The number of biopharmaceutical companies raising venture capital this year has far outpaced the number raising money in public offerings, with 126 venture rounds during the first quarter versus just 22 follow-on public offerings and 10 initial public offerings during the first three months of 2022, according to Biomedtracker.
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
VC Firms Commit More Than $1.9bn To Future Investments
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
